Literature DB >> 1696285

A galactosyl(alpha 1-3)mannose epitope on phospholipids of Leishmania mexicana and L. braziliensis is recognized by trypanosomatid-infected human sera.

J L Avila1, M Rojas.   

Abstract

An immunoglobulin M antibody reactive with galactosyl(alpha 1-3)mannose [Gal(alpha 1-3)Man] residues present on phospholipids extracted from Leishmania mexicana and L. braziliensis was found to be present in high titer in the serum of every normal individual studied. Periodate oxidation, acid hydrolysis, or acetylation suppressed immunoreactivity, suggesting that an oligosaccharide chain was responsible for antibody binding. Interaction occurs only with alpha-Gal terminal residues, since treatment of purified glycophospholipids with alpha-galactosidase but not with beta-galactosidase abolished it. Antibody bound to galactosyl(alpha 1-3)galactose-linked synthetic antigens but did not bind to the same residues present in rabbit, rat, and guinea pig erythrocytes or in murine laminin. Antigen-antibody binding was strongly blocked with Gal(alpha 1-3)Man and Gal(beta 1-4)Man. These results plus inhibition studies with several oligosaccharides suggest that they are indeed different from antibodies against the galactosyl(alpha 1-3)galactose residue. Anti-Gal(alpha 1-3)Man antibody values were significantly elevated in 89% of patients with diffuse cutaneous leishmaniasis, 84% of patients with localized cutaneous leishmaniasis, 69% of patients with mucocutaneous leishmaniasis, and 44 and 62% of patients with Trypanosoma cruzi or T. rangeli infection, respectively, but not in patients with 15 other different infectious and inflammatory diseases. Anti-Gal(alpha 1-3)Man antibody readily absorbed to American Leishmania and Trypanosoma culture forms, suggesting a surface membrane localization of reactive epitope. Gal(alpha 1-3)Man-bearing glycophospholipid was easily extracted from American Leishmania promastigotes and T. cruzi trypomastigotes as well as from American Trypanosoma culture forms. The possibility that this antibody arises against parasitic glycophospholipid-linked Gal(alpha 1-3)Man terminal residues is proposed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696285      PMCID: PMC267983          DOI: 10.1128/jcm.28.7.1530-1537.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Ceramide and inositol content of the lipopeptidophosphoglycan from Trypanosoma cruzi.

Authors:  R M de Lederkremer; O L Casal; C T Tanaka; W Colli
Journal:  Biochem Biophys Res Commun       Date:  1978-12-29       Impact factor: 3.575

2.  Trypanosoma cruzi: defined medium for continuous cultivation of virulent parasites.

Authors:  J L Avila; A Bretaña; M A Casanova; A Avila; F Rodríguez
Journal:  Exp Parasitol       Date:  1979-08       Impact factor: 2.011

3.  The lipid composition of blood and culture forms of Trypanosoma lewisi and Trypanosoma rhodesiense compared with that of their environment.

Authors:  H Dixon; J Williamson
Journal:  Comp Biochem Physiol       Date:  1970-03-01

4.  A sphingolipid having a novel type of ceramide and lacto-N-fucopentaose 3.

Authors:  H J Yang; S I Hakomori
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

5.  Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.

Authors:  J Convit; P L Castellanos; A Rondon; M E Pinardi; M Ulrich; M Castes; B Bloom; L Garcia
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

6.  Defective transport of pyrazolopyrimidine ribosides in insensitive Trypanosoma cruzi wild strains is a parasite-stage specific and reversible characteristic.

Authors:  J L Avila; A Avila
Journal:  Comp Biochem Physiol B       Date:  1987

7.  Gangliosides of human myelin: sialosylgalactosylceramide (G7) as a major component.

Authors:  R W Ledeen; R K Yu; L F Eng
Journal:  J Neurochem       Date:  1973-10       Impact factor: 5.372

8.  Structure of the major carbohydrate fragment of the Leishmania donovani lipophosphoglycan.

Authors:  S J Turco; S R Hull; P A Orlandi; S D Shepherd; S W Homans; R A Dwek; T W Rademacher
Journal:  Biochemistry       Date:  1987-09-22       Impact factor: 3.162

9.  Structural analysis of glycosyl-phosphatidylinositol antigens of Leishmania major.

Authors:  G Rosen; P Påhlsson; M V Londner; M E Westerman; B Nilsson
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

10.  Action of pyrazolopyrimidine derivatives on Trypanosoma rangeli culture forms.

Authors:  J L Avila; M A Polegre; R K Robins
Journal:  Comp Biochem Physiol C       Date:  1986
View more
  4 in total

Review 1.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

Review 2.  Carbohydrate immunity in American trypanosomiasis.

Authors:  L R Travassos; I C Almeida
Journal:  Springer Semin Immunopathol       Date:  1993

3.  Glycoinositol phospholipids from American Leishmania and Trypanosoma spp: partial characterization of the glycan cores and the human humoral immune response to them.

Authors:  J L Avila; M Rojas; A Acosta
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins.

Authors:  Sayonara M Viana; Alba L Montoya; Augusto M Carvalho; Brunele S de Mendonça; Susana Portillo; Janet J Olivas; Nasim H Karimi; Igor L Estevao; Uriel Ortega-Rodriguez; Edgar M Carvalho; Walderez O Dutra; Rosa A Maldonaldo; Katja Michael; Camila I de Oliveira; Igor C Almeida
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.